Comparing Catalent (CTLT) & Its Rivals

Catalent (NYSE: CTLT) is one of 105 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Catalent to similar companies based on the strength of its analyst recommendations, risk, dividends, valuation, profitability, earnings and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Catalent and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catalent 0 2 6 0 2.75
Catalent Competitors 886 3849 6837 181 2.54

Catalent currently has a consensus target price of $44.00, indicating a potential upside of 6.00%. As a group, “Pharmaceuticals” companies have a potential upside of 18.48%. Given Catalent’s competitors higher possible upside, analysts plainly believe Catalent has less favorable growth aspects than its competitors.

Insider & Institutional Ownership

99.4% of Catalent shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 1.7% of Catalent shares are owned by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Catalent and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catalent 5.01% 23.97% 5.24%
Catalent Competitors -2,402.45% -68.50% -7.24%

Risk and Volatility

Catalent has a beta of 1.41, suggesting that its share price is 41% more volatile than the S&P 500. Comparatively, Catalent’s competitors have a beta of 36.16, suggesting that their average share price is 3,516% more volatile than the S&P 500.

Valuation and Earnings

This table compares Catalent and its competitors revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catalent $2.08 billion $109.80 million 48.27
Catalent Competitors $8.17 billion $1.09 billion 149.05

Catalent’s competitors have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Summary

Catalent competitors beat Catalent on 7 of the 13 factors compared.

About Catalent

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply